Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome

BACKGROUND: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterized by arterial or venous thrombosis (or both), and/or pregnancy morbidity in association with the presence of antiphospholipid antibodies. The prevalence of APS is estimated at 40 to 50 cases per 100,000 people....

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cochrane Database Syst Rev
Главные авторы: Bala, Malgorzata M, Celinska-Lowenhoff, Magdalena, Szot, Wojciech, Padjas, Agnieszka, Kaczmarczyk, Mateusz, Swierz, Mateusz J, Undas, Anetta
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley & Sons, Ltd 2020
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC8094585/
https://ncbi.nlm.nih.gov/pubmed/33045766
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012169.pub3
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы